Hepcidin is regulated by promoter-associated histone acetylation and HDAC3

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Pasricha, Sant Rayn ^a,b   Lim, Pei Jin ^a   Duarte, Tiago L ^c   Casu, Carla ^d   Oosterhuis, Dorenda ^e   Mleczko Sanecka, Katarzyna ^f,g,h   Suciu, Maria ^a   Da Silva, Ana Rita ^f,g   Al Hourani, Kinda ^a   Arezes, João ^a   McHugh, Kirsty ⁱ   Gooding, Sarah ^a   Frost, Joe N ^a   Wray, Katherine ^a   Santos, Ana ^c   Porto, Graça ^c,j   Repapi, Emmanouela ^a   Gray, Nicki ^a   Draper, Simon J ⁱ   Ashley, Neil ^a   Soilleux, Elizabeth ^k,l   Olinga, Peter ^e   Muckenthaler, Martina U ^f,g   Hughes, Jim R ^a   Rivella, Stefano ^d   Milne, Thomas A ^a   Armitage, Andrew E ^a   Drakesmith, Hal ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF PORTO   (Portugal)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g Molecular Medicine Partnership Unit (MMPU)   (Germany)

^h INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j UNIVERSITY OF PORTO   (Portugal)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 6; ERYTHROPOIETIN; HAMP1 PROTEIN; HEPCIDIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H3K4ME3; HISTONE H3K9AC; IRON; MESSENGER RNA; NCOR1 PROTEIN; PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; HISTONE;

BONE; CELLS AND CELL COMPONENTS; DRUG; ENZYME; ENZYME ACTIVITY; HOMEOSTASIS; INHIBITION; INHIBITOR; PATHOLOGY; PROTEIN; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DEACETYLATION; ENZYME BINDING; ENZYME INHIBITION; EPIGENETICS; ERYTHROPOIESIS; GENE EXPRESSION; GENE LOCUS; GENE LOSS; GENE REPRESSION; GENE SILENCING; HEMOCHROMATOSIS; HEMOGLOBIN DETERMINATION; HISTONE ACETYLATION; HUH-7 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON RESTRICTION; JAK-STAT SIGNALING; LIVER SLICE; MALE; MOUSE; NONHUMAN; PROMOTER REGION; REGULATORY MECHANISM; RNA SEQUENCE; SPLEEN WEIGHT; THALASSEMIA; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; UPREGULATION; ACETYLATION; ANIMAL; C57BL MOUSE; CHEMISTRY; DEFICIENCY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PROTEIN MOTIF;

MUS;

ACETYLATION; AMINO ACID MOTIFS; ANIMALS; EPIGENESIS, GENETIC; ERYTHROPOIETIN; GENE EXPRESSION REGULATION; HEPCIDINS; HISTONE DEACETYLASES; HISTONES; HUMANS; IRON; MALE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC;

EID: 85028636590     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00500-z     Document Type: Article

References (55)

1. Ganz, T. Systemic iron homeostasis. Physiol. Rev. 93, 1721-1741 (2013).
2. Steinbicker, A. U. & Muckenthaler, M. U. Out of balance - systemic iron homeostasis in iron-related disorders. Nutrients 5, 3034-3061 (2013).
3. Ramos, E. et al. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology 53, 1333-1341 (2011).
4. Meynard, D. et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat. Genet. 41, 478-481 (2009).
5. Andriopoulos, B. Jr. et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat. Genet. 41, 482-487 (2009).
6. Wrighting, D. M. & Andrews, N. C. Interleukin-6 induces hepcidin expression through STAT3. Blood 108, 3204-3209 (2006).
7. Nicolas, G. et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110, 1037-1044 (2002).
8. Kautz, L. et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 46, 678-684 (2014).
9. Kautz, L. et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta-thalassemia. Blood 126, 2031-2037 (2015).
10. Kautz, L. et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 112, 1503-1509 (2008).
11. Silvestri, L. et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 8, 502-511 (2008).
12. Nai, A. et al. Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice. Blood 127, 2327-2336 (2016).
13. Liu, Q., Davidoff, O., Niss, K. & Haase, V. H. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J. Clin. Invest. 122, 4635-4644 (2012).
14. Sonnweber, T. et al. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut 63, 1951-1959 (2014).
15. Bridle, K. R. et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 361, 669-673 (2003).
16. Gardenghi, S. et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 109, 5027-5035 (2007).
17. Jones, E. et al. Hepcidin is suppressed by erythropoiesis in hemoglobin E beta-thalassemia and beta-thalassemia trait. Blood 125, 873-880 (2015).
18. Ganz, T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102, 783-788 (2003).
19. Camaschella, C. Treating iron overload. N. Engl. J. Med. 368, 2325-2327 (2013).
20. Ramos, E. et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood 120, 3829-3836 (2012).
21. van Eijk, L. T. et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 124, 2643-2646 (2014).
22. Turner, B. M. Defining an epigenetic code. Nat. Cell Biol. 9, 2-6 (2007).
23. Miura, K., Taura, K., Kodama, Y., Schnabl, B. & Brenner, D. A. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 48, 1420-1429 (2008).
24. Gaun, V. et al. A chemical screen identifies small molecules that regulate hepcidin expression. Blood Cells Mol. Dis. 53, 231-240 (2014).
25. Mleczko-Sanecka, K. et al. Imatinib and spironolactone suppress hepcidin expression. Haematologica 102, 1173-1184 (2017).
26. Wang, R. H. et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2, 399-409 (2005).
27. West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30-39 (2014).
28. Garnock-Jones, K. P. Panobinostat: first global approval. Drugs 75, 695-704 (2015).
29. Tang, Z. et al. SET1 and p300 act synergistically, through coupled histone modifications, in transcriptional activation by p53. Cell 154, 297-310 (2013).
30. Bishton, M. J. et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 117, 3658-3668 (2011).
31. Corradini, E. et al. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology 54, 273-284 (2011).
32. Anne, M., Sammartino, D., Barginear, M. F. & Budman, D. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther. 6, 1613-1624 (2013).
33. Muckenthaler, M. et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat. Genet. 34, 102-107 (2003).
34. Weizer-Stern, O. et al. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. Am. J. Hematol. 81, 479-483 (2006).
35. Chen, K. et al. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc. Natl Acad. Sci. USA 106, 17413-17418 (2009).
36. de Graaf, I. A. et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat. Protoc. 5, 1540-1551 (2010).
37. Mleczko-Sanecka, K. et al. Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. Blood 123, 1574-1585 (2014).
38. Malvaez, M. et al. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc. Natl Acad. Sci. USA 110, 2647-2652 (2013).
39. Wilson, A. J. et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281, 13548-13558 (2006).
40. Mottis, A., Mouchiroud, L. & Auwerx, J. Emerging roles of the corepressors NCoR1 and SMRT in homeostasis. Genes Dev. 27, 819-835 (2013).
41. You, S. H. et al. Nuclear receptor co-repressors are required for the histone-deacetylase activity of HDAC3 in vivo. Nat. Struct. Mol. Biol. 20, 182-187 (2013).
42. Liu, L., Lin, W., Zhang, Q., Cao, W. & Liu, Z. TGF-beta induces miR-30d down-regulation and podocyte injury through Smad2/3 and HDAC3-associated transcriptional repression. J. Mol. Med. 94, 291-300 (2016).
43. Camaschella, C., Pagani, A., Nai, A. & Silvestri, L. The mutual control of iron and erythropoiesis. Int. J. Lab. Hematol. 38(Suppl 1), 20-26 (2016).
44. Kim, A. & Nemeth, E. New insights into iron regulation and erythropoiesis. Curr. Opin. Hematol. 22, 199-205 (2015).
45. Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res. 21, 381-395 (2011).
46. Sun, Z. et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat. Med. 18, 934-942 (2012).
47. Feng, D. et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 331, 1315-1319 (2011).
48. Wang, Z. et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138, 1019-1031 (2009).
49. Sun, Z. et al. Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. Mol. Cell 52, 769-782 (2013).
50. Alenghat, T. et al. Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456, 997-1000 (2008).
51. Troutt, J. S. et al. Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clin. Chem. 58, 1225-1232 (2012).
52. Bahram, S. et al. Experimental hemochromatosis due to MHC class I HFE deficiency: immune status and iron metabolism. Proc. Natl Acad. Sci. USA 96, 13312-13317 (1999).
53. Nakabayashi, H. et al. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42, 3858-3863 (1982).
54. Sridhar, S. et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J. Virol. 82, 3822-3833 (2008).
55. Douglas, A. D. et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun. 2, 601 (2011).